All patients were previously treated with HHIs (n=84)1
Disease progression/
lack of response2
Intolerance to
HHI therapy2
References: 1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC. 2. Data on file. Regeneron Pharmaceuticals, Inc.